BioMotiv logo

BioMotiv

North America, Ohio, United States, Cleveland

Description

BioMotiv is a therapeutic accelerator developing a portfolio of novel medicines.

Investor Profile

BioMotiv has backed more than 6 startups, with 0 new investments in the last 12 months alone. The firm has led 2 rounds, about 33% of its total and boasts 0 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series A, Series Unknown, Seed rounds (top funding stages).
  • Majority of deals are located in United States, United Kingdom.
  • Strong thematic focus on Biotechnology, Health Care, Medical.

Stage Focus

  • Series A (33%)
  • Series Unknown (33%)
  • Seed (17%)
  • Series B (17%)

Country Focus

  • United States (50%)
  • United Kingdom (50%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Pharmaceutical
  • Therapeutics
  • Biopharma
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does BioMotiv frequently co-invest with?

Ridgeback Capital
North America, New York, United States, New York
Co-Investments: 1
Ionis Pharmaceuticals
North America, California, United States, Carlsbad
Co-Investments: 1
Advent Life Sciences
Europe, England, United Kingdom, London
Co-Investments: 2
Northpond Ventures
North America, Maryland, United States, Bethesda
Co-Investments: 1
European Investment Fund
Europe, Luxembourg, Luxembourg, Luxembourg
Co-Investments: 1
Biotechnology Value Fund
North America, California, United States, San Francisco
Co-Investments: 1
Johnson & Johnson Robotics and Digital Solutions
North America, New Jersey, United States, New Brunswick
Co-Investments: 2
CH
North America, New York, United States, New York
Co-Investments: 1
Scottish Investment Bank
Europe, Glasgow City, United Kingdom, Glasgow
Co-Investments: 1
HealthCap
Europe, Stockholms Lan, Sweden, Stockholm
Co-Investments: 1

What are some of recent deals done by BioMotiv?

Amphista Therapeutics

Cambridge, Cambridgeshire, United Kingdom

Amphista Therapeutics operates as a biopharmaceutical company.

BiopharmaBiotechnology
Series BMar 17, 2021
Amount Raised: $53,000,000
Aro Biotherapeutics

Philadelphia, Pennsylvania, United States

Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.

BiotechnologyHealth CareMedicalPharmaceuticalTherapeutics
Series AJan 5, 2021
Amount Raised: $88,000,000
Amphista Therapeutics

Cambridge, Cambridgeshire, United Kingdom

Amphista Therapeutics operates as a biopharmaceutical company.

BiopharmaBiotechnology
Series AApr 7, 2020
Amount Raised: $7,500,000
Aro Biotherapeutics

Philadelphia, Pennsylvania, United States

Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.

BiotechnologyHealth CareMedicalPharmaceuticalTherapeutics
Series UnknownDec 11, 2018
Amount Raised: $13,000,000
Allinaire Therapeutics

Cleveland, Ohio, United States

Allinaire Therapeutics aims to develop novel therapeutics for Chronic Obstructive Pulmonary Disease (COPD) and other pulmonary diseases.

BiotechnologyHealth CareTherapeutics
SeedJan 27, 2017
Amount Raised: $1,570,000
Orca Pharmaceuticals

Abingdon, Oxfordshire, United Kingdom

Orca Pharmaceuticals is a new biotechnology startup focusing on treating autoimmune diseases.

BiotechnologyHealth CareMedicalPharmaceutical
Series UnknownApr 28, 2014
Amount Raised: $1,300,000